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Niacin is delivered to blood capillary cells
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(Cells and Non-cellular
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Matrix Protein Fibers Such
.
as Collagen and Elastln)

capillaries that results in an increased supply
of oxygen in the dermis where it supports
energy metabolism of dermal fibroblasts
The increased oxygen in the dermis diffuses

into the epidermis where it supports energy

metabolism in epidermal keratinocytes
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METHODS AND COMPOSITIONS USEFUL
IN ENHANCING OXYGEN DELIVERY TO
CELLS

species (ROS hereafter) is involved in the pathophysiology
of skin deterioration. ROS include, inter alia, superoxides,

the hydroxyl radical, hydrogen peroxide, singlet oxygen,
nitric oxide, peroxynitrite, and hypochlorite. See, e.g.,

RELATED APPLICATION

Simonian, et al., Ann. Rev. Pharmacol. Toxicol. 36:83—106

This application claims priority of provisional application
Ser. No. 60/197,227, ?led Apr. 14, 2000, incorporated by

(1996), incorporated by reference. All cells are exposed to
ROS during the normal course of energy metabolism, via
environmental exposure and/or immune surveillance. While
ROS are involved in normal cell signaling pathWays, eleva

reference.
FIELD OF THE INVENTION

10

This invention relates to methods that are useful in

tion of ROS during oxidative stress disrupts signaling
pathWays, often resulting in cell death by apoptosis or

improving the delivery of oxygen to tissues and organs, such

necrosis. Thus, it is likely that ROS are involved in the

as skin. Therapeutic uses of the method are disclosed as

decrease in cell number observed over time, even in sun

protected skin.

Well.
15

BACKGROUND AND PRIOR ART

The skin plays multiple roles in protection from environ
mental insults. Environmental exposure results in the pro

gressive deterioration of skin that is initially cosmetic but
can lead to end stage diseases such as actinic keratosis and

20

skin cancer. Hereinafter, While the skin Will be discussed
speci?cally, it is to be understood that the remarks are

applicable to organs and tissues in general.
Health of skin, as Well as other tissues and organs, is

dependent upon supplies of many essential nutrients to

25

cellular components Which are a part thereof, oxygen in
particular, as Well as the ef?cient removal of Waste products
such as carbon dioxide, and other metabolic end products.

An optimal supply of oxygen is required in order to support
metabolic pathWays Which inter alia, support the cellular

repair mechanisms in maintaining the genomic integrity of
35

40
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both the epidermis and dermis become thinner With a loss of
cell numbers and connective tissue, leading to the appear
ance of ?ne Wrinkles. Ultraviolet (UV) irradiation from the

FIG. 1 depicts the skin, in cross section, in combination
With an illustration of the delivery system of the invention.
FIG. 2 depicts data obtained in accordance With the
invention, via the use of a transcutaneous oxygen monitor.

FIG. 3 shoWs results from a further experiment, using the

sun causes photodamage that accelerates skin deterioration.

transcutaneous oxygen monitor.
60

FIG. 4 shoWs data from an experiment shoWing that
niacin esters are converted to niacin in order to improve skin

oxygenation.

deterioration including pre-malignant lesions termed actinic
de?ned as an abnormal accumulation of reactive oxygen

HoW these aspects of the invention are met Will be seen

from the disclosure Which folloWs.
BRIEF DESCRIPTION OF THE FIGURES

at Which one stage progresses to the next varies greatly from

Compelling evidence noW indicates that oxidative stress,

improved. Hence, one object of the invention is a method for
improving delivery of oxygen to tissues and organs, such as
skin. Yet a further aspect of the invention are compositions
useful in achieving this goal. Still a further aspect of the
invention is the treatment of conditions Where improved

oxygenation is called for, via application of the methods and
compositions of the invention.

skin texture and the appearance of age spots, folloWed by
changes in elasticity that lead to the appearance of skin
Wrinkles. The age at Which these changes appear and the rate

keratosis and skin cancer.

important for alleviating the problems discussed herein. It is
desirable to have a method available by Which oxygen
delivery to a tissue or organ, such as the skin, can be

As people age, progressively deleterious changes in skin

In contrast to the thinning observed in sun-protected skin,
photodamaged skin has a thickened and rough appearance
With an increase in deeper skin Wrinkling Which occurs in
dermal tissue. Photodamage also causes end-stage skin

organs and tissues subjected to genotoxic stress caused by,
e.g., ROS, including skin.
The delivery of oxygen is important for proper mainte
nance of cell energy metabolic pathWays, Which in turn is

appearance occur. The initial changes are the loss of smooth 50

individual to individual. During the normal aging process,

deterioration, as they are components of many skin creams.

Also, cells contain complex mechanisms for the mainte
nance of genomic integrity. Of particular interest herein is
the accumulating evidence for the involvement of DNA

keratinocytes are the major cell type. Dermal ?broblasts are

embedded Within a matrix comprised of collagen, elastin,
proteoglycans, and other extracellular matrix molecules.
Blood capillaries are found in the dermis, but the epidermis
is non-vascular.

of particular interest in that unrepaired damage can lead to
the loss of skin cells and to altered functioning of cells that
survive genotoxic stress.
While some changes in skin during aging can not be
avoided, much skin deterioration at an early age is avoid
able. Skin cells contain a number of protective mechanisms
for the prevention and repair of ROS damage to DNA and
protein. For example, a number of intracellular molecules,
including glutathione and the antioxidant vitamins C and E
play key roles in scavenging ROS before they can react With
cellular macromolecules. Indeed, the antioxidant vitamins

have already found application in the prevention of skin
30

mechanisms that lead to resistance of skin deterioration.
The delivery of oxygen to skin via blood circulation is
distal to delivery to most other organs. Further, the upper

most living layer of skin, i.e., the “epidermis,” is non
vascular. This leaves the upper layers of skin at high risk of
receiving insuf?cient oxygen.
Skin is a complex organ system, consisting of multiple
layers. The uppermost, or “stratum corneum” layer, consists
of non-living material derived primarily from the terminal
differentiation of epidermal keratinocytes, and provides a
protective barrier for the underlying components of skin.
The epidermis contains a number of cell types, although

Exposure to the ultraviolet rays of sunlight is a major
source of skin oxidative stress. TWo major targets for dam
age by ROS in skin are DNA and protein. DNA damage is

65

DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS

The invention described herein involved various formu
lations designed to enhance delivery of oxygen to tissues

US 6,924,299 B2
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and organs, such as the skin. The compositions are formu
lated so as to partition rapidly into a layer, such as the
stratum corneum layer of the skin, at a rate Which permits
sustained delivery of an active agent or agents to, e.g., the
epidermis, in a sustained fashion and at a concentration

at concentrations as loW as 0.1%, While C9 and C10 alkyl
esters caused vasodilation at 1.0% formulations. The longer

chain esters, i.e., those at C12 or higher, did not provoke
vasodilation at either concentration.
The onset and duration of vasodilation Was determined,

Which provokes capillary dilation. As a result of capillary

again by visual determination, for C2, C6, and C8 alkyl

dilation, blood ?oW increases, thereby increasing oxygen

esters. Results are set forth in Table 2. Note that the log P

tension in the dermis Which in turn supports both energy

values provided for the C9 and C11 compounds are derived
from a plot of experimentally determined values for other

metabolism in epidermal ?broblasts, and epidermal kerati
nocytes When the skin is involved, and other parallel cell

10

types When other tissues and/or organs are involved.
The highly lipophilic nature of the stratum corneum
dictates that the desired oxygen enhancing agent must be

compounds. The C8 compound provided the longest effect.
Thus, niacin esters With log P values of less than 6.0 are
preferred. Most preferred are esters With log P values in the
range of from about 4.5 to about 5.5.

sufficiently lipophilic to effectively partition into the stratum
corneum from the donor compartment, Which may be, e.g.,

15

a skin cream or lotion. This necessitates the preparation of
a distinct lipophilic agent, such as those described in more
detail infra. Diffusion from the stratum corneum into the

Properties of Niacin Esters
Alkyl Carbon

epidermis also requires that the agent should be suf?ciently
lipophilic to rapidly partition from the cream or lotion into

20

the stratum corneum. Niacin esters are exempli?ed herein.

Lipophilic derivatives of niacin esters can be prepared, and
these are converted into active niacin esters folloWing dif
fusion out of the stratum corneum into the epidermis;

hoWever, other materials could also be used. The lipophi
licity of the agent should alloW it to be formulated in, e.g.,

TABLE 1

25

Chain Length
1
2
4
6
8
9
10

carbon
carbons
carbons
carbons
carbons
carbons
carbons

Vasodilation at

Log P Value"

0.1%

1.0%

0.84
1.3
2.4
3.5
4.8
5.0"
5.8

Yes
Yes
Yes
Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes

skin cream or lotion and the ester linkage should be very

11 carbons

6.0"

No

Slight

stable in these formulations to, e.g., chemical hydrolysis

12
13
14
15
16

carbons
carbons
carbons
carbons
carbons

6.6
7.5
7.6
8.3
9.2

No
No
No
No
No

No
No
No
No
No

18 carbons

9.7

No

No

under aqueous conditions.
The experiments Which folloW set forth the invention in
greater detail, but should not be construed as limiting the
invention in any Way.

30

EXAMPLE 1

Nicotinic acid esters Were synthesiZed in accordance With

35

Ser. No. 09/452,617, ?led Dec. 1, 1999, incorporated by

TABLE 2
Vasodilation Properties of Selected Niacin Esters

reference. In brief, nicotinoyl chloride Was combined With

triethylamine (TEA), dimethylaminopyridine (DMAP), and

Vasodilation Effect at 0.1%

various alkyl alcohols, under nitrogen. Esters resulting from
the synthesis Were separated via silica gel column
chromatography, and converted to HCl salts for further
puri?cation, using standard methods. The purity Was con
?rmed via thin layer chromatography, and 1H-NMR.
The Pod/W values for these compounds Were determined in
accordance With Harnisch, et al., J. Chromatog.

Niacin Ester

Onset

Duration

Ethyl niacin
Hexyl niacin
Octyl niacin

5-10 min
10-15 min
10-20 min

30-45 min
60-90 min
240-360 min

45

282:315-332 (1983), incorporated by reference. This refer

EXAMPLE 3

ence also describes determination of “log P” values,
described infra.

that provide sustained vasodilation folloWing topical appli

EXAMPLE 2

The experiments reported in Table 1 reveal compounds
50

This example details the ?rst of tWo sets of experiments
designed to determine the vasodilation effect of alkyl niacin
esters. Formulations Were prepared by combining the alkyl

cation; hoWever, they do not indicate Whether the vasodila
tion effect is accompanied by an increased release of oxygen
into the skin tissue. To examine this issue, the oxygen
content of skin to Which the octyl ester discussed supra Was

determined directly, using a transcutaneous oxygen monitor.

esters referred to supra in a skin lotion, at 0.1% and 1.0% 55 The 1% formulation of the octyl ester Was applied to skin for

concentrations. The lotions Were applied topically to the skin

30 minutes. After this thirty minute period, the skin Was
cleaned With soap and Water, Wiped With an alcohol sWab,

of human volunteers on the anterior surface of a forearm.

Vasodilation Was observed visually, i.e., by observing blush

and a drop of deioniZed Water Was placed on the sensor

ing at the site of application, or lack thereof. Both onset and
duration of vasodilation Were measured.
The results for the esters tested are set forth in Table 1,

surface before its attachment to the anterior surface of the
60

volunteers’ forearms. The transcutaneous values Were

recorded constantly, and stored by the instrument. The

Which folloWs. This table includes lipophilicity of the tested

monitor measures relative oxygen content, because the tem

compounds, in log P values, folloWing Harnisch, et al.,

perature at Which the monitor operates does impact the

supra, incorporated by reference, as Well as the results of
visual observation.
It Will be seen that small chain alkyl esters, i.e., those With
8 carbon atoms or less in the alkyl chain, caused vasodilation

oxygen permeability of the stratum corneum. See, e.g.,
65

Martin, Resp. Care 35:577-589 (1990), incorporated by
reference. The sensor Was calibrated at 4 hour intervals, or

Whenever the sensor temperature Was changed.

US 6,924,299 B2
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The results of one set of experiments are presented in FIG.
2. The monitor Was operated at a temperature of 40° C.
Values are given for both a control, and the formulation
described herein.

from 6 to 12 carbon atoms, preferably 8 to 10, and most
preferably 8 carbon atoms. Such molecules also function in
the Way the niacin esters function. Alcohol analogs of niacin
cause vasodilation, and the ester derivatives act in the same
Way as the ester described supra.
“Derivative” as used herein refers to any chemical modi

The ?rst, high value is representative of oxygen tension of
air in the monitor probe at the time of application, and then
drops rapidly to a very loW value, demonstrating loW skin

?cation of the base, vasodilator compound Which results in
a molecule With the permeation qualities described supra,
e.g., a log P values beloW about 6.0 Esters of compounds

oxygen content. This Was folloWed by an increase and a

plateau, Which is attributed to the effect of simply operating
the monitor at 40° C. The depicted results then shoW a
sustained increase in skin oxygen as a result of application
of the niacin ester. Comparison of the results for the control
and the test compound shoW a clear increase in the amount

10

creams, lotions, salves, balms, roll-on sticks, shampoos,

of oxygen being delivered to the capillaries.
In a folloW-up experiment, the monitor Was operated at
38° C., and both O2 and CO2 Were measured, With a
combined transcutaneous oxygen and CO2 monitor. FIG. 3

15

about 5.0% by Weight. Most preferably, the formulation is

by Weight to about 1.0% by Weight.
20

These formulations are useful in the treatment of condi

tions Where improved or enhanced oxygenation of tissue is
desirable. Such conditions Will be Well knoWn to the skilled
artisan.
Enhanced oxygenation, as discussed supra, enhances

that the topical application is also enhancing removal of
metabolic products. While the results of skin oxygen and
CO2 measurements are consistent With the observed vasodi
25

does not necessarily indicate an increased release of oxygen

into the skin tissue; hoWever, the results disclosed in FIGS.
2 and 3 demonstrate that application of the niacin esters
effects both increased blood flow into skin and increased
release of oxygen into the skin.

composition in the formulation Will vary. Preferably,
one Where the ester concentration ranges from about 0.1%

the application of the niacin ester. The latter result indicates

lation reported in Table 1, observation of vasodilation alone

Washes, suppositories, and so forth. The amount of the active

hoWever, the concentration Will range from about 0.05% to

presents these results. The control is represented by the
dotted line. The results shoW a sustained increase in skin
oxygen content, and a decrease in CO2 content as a result of

such as acid and alcohol esters, are exemplary of such

molecules, but are not the only such compounds.
The active ingredient may be applied in any of the
standard, topical formulations Well knoWn to the art, such as

other processes Within the organ. Hence, a further feature of
the invention is the use of the formulations, described supra,
in combination With materials such as nutrients,

micronutrients, pharmaceutical agents, and other materials
Where enhanced oxygen delivery Will improve the efficacy
30

EXAMPLE 4

of the additional material. Of particular interest are com
pounds and formulations, such as nicotinic acid esters Which

have log P values in the range described, supra. The art is

Previous Work by Sugibayashi, et al., J. Controlled
Release 62:201—208 (1999) has shoWn that, With respect to

familiar With hoW to determine the log P values, as Was

shoWn via the citation to, e.g., Harnisch, et al., supra and

skin, there is little or no esterase activity in the stratum 35 need not be reiterated here. Similarly, a methodology is set
corneum, the epidermis has highest activity, and the dermis
forth herein Which shoWs the skilled artisan hoW to deter
has reduced activity relative to the epidermis. As such,
mine if a particular compound, such as a nicotinic acid ester,
experiments Were undertaken to determine if esters require
increases and/or improves oxygenation. Alkyl esters of
conversion to other molecules in order to provoke oxygen
nicotinic acid have been described herein; hoWever, other
ation. An experiment demonstrating that niacin esters 40 materials, including other nicotinic acid esters can be used
require conversion to niacin in order to achieve skin oxy
as Well, as long as they satisfy the criteria that are adduced
genation is shoWn in FIG. 4. Parallel experiments Were
herein.
carried out using 0.1% octyl niacin ester lotion, and a lotion
Other aspects of the invention Will be clear to the skilled
containing octyl niacin ester (0.1%), and 0.1% butyl ben
artisan and need not be set forth herein.

Zoate. Butyl benZoate has a log P value of 3.5, as compared
to a value of 4.8 for the octyl ester, suggesting faster
partitioning into the epidermis. The presence of the inactive

45

ester, i.e., butyl benZoate, blocked the increase in oxygen
content, demonstrating that the conversion of niacin ester to
niacin is required. This also shoWs that inactive co-esters can
be used the modulate the oxygenation effect.

excluding any equivalents of the features shoWn and
described or portions thereof, it being recogniZed that vari
50

ous modi?cations are possible Within the scope of the
invention.
We claim:
1. Amethod for enhancing delivery of oxygen to a tissue,
comprising administering to said tissue a nicotinic acid alkyl

55

ester containing composition, Wherein the alkyl group of

Oxygen content Was measured in the same Way as is

described, supra, or using other techniques knoWn to the art.

The foregoing examples describe the invention, Which
relates to methods and compositions for increasing oxygen
delivery to cells. Brie?y, these require the use of a derivative

said nicotinic acid alkyl ester consists of from 8 to 10 carbon

of a vasodilator compound, Wherein the derivative has a

structure such that improved permeation of the vasodilator
compound is achieved. In the case of niacin, esters are
preferred. Any ester Which is a substrate for an indigenous
esterase may be used, and is a part of the invention.

60

atoms, Wherein said composition contains from about 0.05 %
to about 5.0% by Weight of said compound, in an amount
sufficient to enhance oxygen delivery to said tissue.
2. The method of claim 1, Wherein said nicotinic acid

alkyl ester is applied topically.

Especially preferred is the octyl ester of niacin. Especially
preferred are esters Which have log P values, as described
supra, Which are loWer than about 6.0, more preferably from
about 4.5 to about 5.5.
Also a part of the invention is the use of esteri?ed, alcohol
analogs of nicotinic acids, Wherein the ester group contains

The terms and expressions Which have been employed are
used as terms of description and not of limitation, and there
is no intention in the use of such terms and expressions of

65

3. The method of claim 1, Wherein said tissue is skin.
4. The method of claim 1, Wherein said nicotinic acid
alkyl ester is nicotinic acid octyl ester.
5. The method of claim 1, Wherein said composition
contains from about 0.1% to about 1% by Weight of said

compound.

US 6,924,299 B2
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6. The method of claim 1, wherein said composition is a
cream, a lotion, a salve, a balm, a roll-on stick, a Wash, or

a suppository.

7. The method of claim 1, Wherein said composition
further comprises butyl benZoate in an amount sufficient to

modulate oxygenation by inhibiting conversion of said nico
tinic acid alkyl ester to nicotinic acid.
8. The method of claim 1, Wherein said alkyl group of said
nicotinic acid alkyl ester consists of 8 carbon atoms.

5

9. The method of claim 1, Wherein said alkyl group of said
nicotinic acid alkyl ester consists of 9 carbon atoms.
10. The method of claim 1, Wherein said alkyl group of
said nicotinic acid alkyl ester consists of 10 carbon atoms.
11. The method of claim 1, Wherein said composition
enhances delivery of oXygen for at least 4 hours.

